PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1498792
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1498792
Cell & Gene Therapy Cold Chain Logistics Market size was valued at USD 1,451.2 Million in 2023, expanding at a CAGR of 12.00% from 2024 to 2032.
The cell & gene therapy cold chain logistics market is a market segment with a focus on strictly ensuring the handling and transportation of sensitive biological products in strictly temperature-controlled environments during logistics processes, thereby preventing any form of degradation leading to a loss of potency and ensuring their therapeutic value and effectiveness. It provides specialized logistics and supply chain services concerning the transportation, storage, and distribution of cell and gene therapy products requiring specified temperature-controlled environments to support their efficacy and integrity. The logistics providers in this market play a very important role in maintaining cold chain integrity during the entire supply chain for successful deliveries of cell and gene therapies to patients.
Cell & Gene Therapy Cold Chain Logistics Market- Market Dynamics
Personalized Medicine Boom Propels the Cell and Gene Therapy Supply Chain and Logistics Market
The growing need for personalized treatment is projected to drive the cell and gene therapy supply chain/logistics industry in the coming years. Personalized medicine is a novel approach to medical treatment and care that tailors medical decisions, procedures, interventions, and pharmacological regimens to each patient. The cell and gene therapy supply chain/logistics are utilized to deliver precision medications to each patient's unique needs safely and effectively, with temperature monitoring to ensure supply chain integrity. For instance, STAT, a health-oriented news outlet based in the United States, reported that there were more than 75,000 genetic testing items and 300 tailored medicines in October 2022. As a result, the growing desire for personalized medicine is fueling the expansion of the cell and gene therapy supply chain/logistics industry.
Cell & Gene Therapy Cold Chain Logistics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.00% over the forecast period (2024-2032)
Based on Component segmentation, Cryogenic Shippers was predicted to show maximum market share in the year 2023
Service-based Transportation was the most popular segment in 2023.
In 2023, air transportation was the most popular mode of transportation.
In 2023, cryogenic was the most common holding temperature range segment.
In 2023, Pharmaceutical and Biotechnology Companies were the leading end-user segment.
On the basis of region, North America was the leading revenue generator in 2023
The Global Cell & Gene Therapy Cold Chain Logistics Market is segmented on the basis of Component, Services Offered, Mode of Transportation, Holding Temperature Range, End User, and Region.
The market is divided into seven categories based on Components: Cryogenic Shippers, Cryogenic Storage Freezers, Cryogenic Packout Kits, Cold Chain Management Systems, Ultra-Low Freezers, Shipment and Storage Medium, and Others. Cryogenic shippers are developing as a major segment. Cryogenic shippers, which provide ultra-low temperature storage conditions throughout shipping, play an important role in preserving the integrity and efficacy of delicate biological materials such as cell and gene treatments. These customized containers use cryogenic technology to keep temperatures as low as -196°C (-320.8°F), preserving biological materials without jeopardizing their viability or functionality. Cryogenic shippers provide various benefits that make them essential components of the cell and gene therapy cold chain logistics ecosystem. They offer a dependable and secure method of shipping temperature-sensitive goods across great distances, including international shipments.
The market is divided into three categories based on Services Offered: Transportation, Storage and Packaging. Transportation emerges as a prominent category due to its critical role in assuring the safe and timely delivery of temperature-sensitive biologics. Transportation refers to the transfer of cellular materials, gene treatments, and other goods from manufacturing facilities to distribution centers, clinical sites, and, eventually, patients. As cell and gene treatments gain significance in the therapeutic landscape, there is an increased demand for specialized transportation systems that can maintain perfect temperature control throughout the supply chain. Temperature-controlled transportation is crucial for preserving the efficacy and safety of medicines that need ultra-low temperatures.
Cell & Gene Therapy Cold Chain Logistics Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America, notably the United States, dominates the worldwide cell and gene therapy cold chain logistics market. Several reasons contribute to North America's leadership in this field. The United States leads the way in cell and gene therapy innovation and research thanks to a strong ecosystem that includes prominent pharmaceutical corporations, biotechnology enterprises, academic institutions, and research organizations. The country has a large pipeline of cell and gene therapy products in various stages of development and commercialization, which increases need for specialist cold chain logistics services.
The Asia Pacific region is likely to have the fastest CAGR in the Cell & Gene Therapy Cold Chain Logistics Market. This reflects the increasing need and importance of cold chain logistics within the region to support the transportation and storage of temperature-sensitive cell and gene therapy products. It reflects the growing advancements and adoption of these innovative therapies in Asia Pacific, driving the need for efficient and reliable logistics solutions to maintain the integrity of these valuable products during transportation and storage.
In the competitive landscape of the Cell & Gene Therapy Cold Chain Logistics Market, some several key players and companies provide specialized services to support the transportation and storage of cell and gene therapy products. These companies often offer comprehensive cold chain logistics solutions tailored to the unique requirements of these advanced therapies. Some of the prominent players in this market include Cencora, Inc., United Parcel Service, Inc., Catalent, Inc., and BioLife Solutions, Inc. These companies have established expertise in managing the complexities of cold chain logistics for cell and gene therapies. They ensure that these products are handled with the utmost care and precision to maintain their quality and efficacy from manufacturing facilities to clinical sites or patients' locations.
In January 2023, Catalent, Inc. introduced its latest service, the Case Management Service. This service is designed to handle the unique issues associated with assuring the secure and timely delivery of cutting-edge therapies to patients. It provides experienced supply chain management from project initiation to conclusion.
GLOBAL CELL & GENE THERAPY COLD CHAIN LOGISTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Cencora, Inc.
United Parcel Service, Inc.
Catalent, Inc.
BioLife Solutions, Inc.
Cryoport System LLC.
Atelerix Ltd.
Life Science Group Ltd (LSG)
Yourway Biopharma Services Company
Bertelsmann SE & Co. KGaA
NMDP BioTherapies
Others